Literature DB >> 9541504

Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor.

M F Linton1, A H Hasty, V R Babaev, S Fazio.   

Abstract

According to the secretion-capture model of remnant lipoprotein clearance, apo E secreted by hepatocytes into the space of Disse serves to enrich the remnants with a ligand for receptor-mediated lipoprotein endocytosis. Current evidence supports a two-receptor model of lipoprotein removal, in which apo E-containing remnants bind either the low density lipoprotein receptor (LDLR) or the LDLR-related protein (LRP). Recently, we demonstrated that reconstitution of apo E(-/-) mice with apo E(+/+) marrow results in normalization of plasma lipoprotein levels, indicating that hepatic expression of apo E is not required for remnant clearance and calling into question the relevance of the secretion-capture mechanism. To dissect the relative contributions of LDLR and LRP to the cellular catabolism of remnant lipoproteins by the hepatocyte, bone marrow transplantation (BMT) was used to reconstitute macrophage expression of apo E in mice that were null for expression of both apo E and the LDLR. Reconstitution of macrophage apo E in apo E(-/-)/LDLR(-/-) mice had no effect on serum lipid and lipoprotein concentrations, although it produced plasma apo E levels up to 16-fold higher than in C57BL/6 controls. Immunocytochemistry of hepatic sections revealed abundant staining for apo E in the space of Disse, but no evidence of receptor-mediated endocytosis of remnant lipoproteins. Transient expression of human LDLR in the livers of apo E(+/+)--> apo E(-/-)/LDLR(-/-) mice by adenoviral gene transfer resulted in normalization of serum lipid levels and in the clearance of apo E-containing lipoproteins from the space of Disse. We conclude that whereas the LDLR efficiently clears remnant lipoproteins irrespective of the site of origin of apo E, endocytosis by the chylomicron remnant receptor (LRP) is absolutely dependent on hepatic expression of apo E. These data demonstrate in vivo the physiologic relevance of the apo E secretion-capture mechanism in the liver.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541504      PMCID: PMC508755          DOI: 10.1172/JCI2181

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects.

Authors:  D C Rubinsztein; J C Cohen; G M Berger; D R van der Westhuyzen; G A Coetzee; W Gevers
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

2.  NHLBI funding policies. Enhancing stability, predictability, and cost control.

Authors:  C Lenfant
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

3.  Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice.

Authors:  H Shimano; Y Namba; J Ohsuga; M Kawamura; K Yamamoto; M Shimada; T Gotoda; K Harada; Y Yazaki; N Yamada
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

4.  Hepatic lipase treatment of chylomicron remnants increases exposure of apolipoprotein E.

Authors:  D L Brasaemle; K Cornely-Moss; A Bensadoun
Journal:  J Lipid Res       Date:  1993-03       Impact factor: 5.922

5.  Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor.

Authors:  T Kita; J L Goldstein; M S Brown; Y Watanabe; C A Hornick; R J Havel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

6.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

Authors:  A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

7.  Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo.

Authors:  S Y Choi; L G Fong; M J Kirven; A D Cooper
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

8.  Familial apolipoprotein E deficiency.

Authors:  E J Schaefer; R E Gregg; G Ghiselli; T M Forte; J M Ordovas; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

9.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

Authors:  S H Zhang; R L Reddick; J A Piedrahita; N Maeda
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

10.  Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation.

Authors:  W A Boisvert; J Spangenberg; L K Curtiss
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

View more
  23 in total

1.  The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice.

Authors:  Charles W Joyce; Marcelo J A Amar; Gilles Lambert; Boris L Vaisman; Beverly Paigen; Jamila Najib-Fruchart; Robert F Hoyt; Edward D Neufeld; Alan T Remaley; Donald S Fredrickson; H Bryan Brewer; Silvia Santamarina-Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages.

Authors:  Paul A Mueller; Lin Zhu; Hagai Tavori; Katherine Huynh; Ilaria Giunzioni; John M Stafford; MacRae F Linton; Sergio Fazio
Journal:  Circulation       Date:  2018-10-23       Impact factor: 29.690

3.  ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium.

Authors:  Nathalie Gaudreault; Nikit Kumar; Jessica M Posada; Kyle B Stephens; Nabora Soledad Reyes de Mochel; Delphine Eberlé; Victor R Olivas; Roy Y Kim; Matthew J Harms; Sean Johnson; Louis M Messina; Joseph H Rapp; Robert L Raffai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-03       Impact factor: 8.311

4.  Apo E structure determines VLDL clearance and atherosclerosis risk in mice.

Authors:  C Knouff; M E Hinsdale; H Mezdour; M K Altenburg; M Watanabe; S H Quarfordt; P M Sullivan; N Maeda
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

5.  Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat.

Authors:  G Asset; B Staels; R L Wolff; E Baugé; Z Madj; J C Fruchart; J Dallongeville
Journal:  Lipids       Date:  1999-01       Impact factor: 1.880

6.  Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.

Authors:  Hagai Tavori; Daping Fan; Ilaria Giunzioni; Lin Zhu; MacRae F Linton; Agnes B Fogo; Sergio Fazio
Journal:  J Lipid Res       Date:  2014-09-02       Impact factor: 5.922

7.  LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice.

Authors:  K C Yu; W Chen; A D Cooper
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

8.  ApoE derived from adipose tissue does not suppress atherosclerosis or correct hyperlipidemia in apoE knockout mice.

Authors:  Zhi H Huang; Catherine A Reardon; Papasani V Subbaiah; Godfrey S Getz; Theodore Mazzone
Journal:  J Lipid Res       Date:  2012-10-15       Impact factor: 5.922

9.  Human LDL receptor enhances sequestration of ApoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice.

Authors:  Michael Altenburg; Jose Arbones-Mainar; Lance Johnson; Jennifer Wilder; Nobuyo Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-27       Impact factor: 8.311

10.  Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.

Authors:  M M Véniant; C H Zlot; R L Walzem; V Pierotti; R Driscoll; D Dichek; J Herz; S G Young
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.